20231030-国盛证券-医药生物行业专题研究_医药新需求大单品梳理之二_RSV疫苗_7页_545kb

Summary of RSV Vaccine Report

RSV Overview

• RSV (Respiratory Syncytial Virus) is a common virus causing respiratory infections. It poses a significant health burden, particularly for infants under 5 years and people aged 65 and older, leading to severe conditions like acute lower respiratory infections, hospitalizations, and long-term complications.

Vaccine Development Progress

• RSV vaccine development has evolved through challenges, with key setbacks from early attempts like Pfizer's FI-RSV in the 1960s, which caused adverse effects.
• In 2023, breakthroughs occurred with GSK's Arexvy and Pfizer's Abrysvo receiving FDA approvals, marking the first authorized RSV vaccines globally. These vaccines show high efficacy in reducing severe RSV-related diseases, with potential market entry in China expected.

Domestic Market Potential

• China lacks approved RSV vaccines domestically, with GSK's Arexvy progressing through regulatory steps, possibly via collaboration with Sinopharm.
• If successful, these vaccines could address a large market, potentially becoming a billion-yuan revenue drug due to the vast elderly population and pediatric needs in China, with varying sales projections based on penetration rates and pricing.

Risk Assessment

• Key risks include unexpected negative policies, subpar industry growth, and uncertainty in sales forecasts, which could impact vaccine uptake and revenue.